SML3808
Firategrast
≥98% (HPLC)
别名:
SB 683699, T 0047, T-0047, (αS)-α-[(2,6-Difluorobenzoyl)amino]-4′-(ethoxymethyl)-2′,6′-dimethoxy[1,1′-biphenyl]-4-propanoic acid, (S)-2-(2,6-Difluorobenzamido)-3-(4′-(ethoxymethyl)-2′,6′-dimethoxy-[1,1′-biphenyl]-4-yl)propanoic acid, SB-683699
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Firategrast is an orally available, potent and selective antagonist of α4β1/α4β7 integrins. Firategrast inhibits α4β1/α4β7 integrin-mediated transferring of lymphocytes into the central nervous system (CNS). In phase II trial it demonstrated a reduction of new contrast enhancing MRI lesions in patients with relapsing remitting MS.
Orally available, potent and selective antagonist of α4β1/α4β7 integrins
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
Lancet Neurology, 11(2), 131-139 (2012)
Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer
BMC Cancer, 22(1), 692-692 (2022)
Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis
Journal of Internal Medicine, 289(6), 771-791 (2021)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持